Last updated: March 13, 2026
What is NDC 49348-0511?
NDC 49348-0511 is identified as an injectable formulation of Itolizumab, marketed under the brand name Alzumab. Developed by Biocon, Alzumab is a monoclonal antibody used primarily for the treatment of autoimmune conditions such as moderate to severe plaque psoriasis and other off-label indications.
Market Overview
Indications and Therapeutic Area
Itolizumab is indicated for:
- Moderate to severe plaque psoriasis
- Other autoimmune disorders (investigational and off-label uses)
Competitive Landscape
The monoclonal antibody (mAb) space in autoimmune therapy includes:
- Humira (adalimumab) – annual sales exceeded $20 billion pre-2023
- Cosentyx (secukinumab) – around $5 billion/year
- Stelara (ustekinumab) – approx. $7 billion/year
Itolizumab faces competition primarily from these established products, but it targets specific pathways to differentiate itself.
Regulatory Status
- Approved in India (by the Central Drugs Standard Control Organization, CDSCO)
- Approved in Europe (Mexican regulatory agency approval)
- Under clinical evaluation in the U.S. (phase 3 trials ongoing)
Market Penetration
- India: Commercialized through Biocon, with early adoption in psoriasis clinics
- Other regions: Limited due to regulatory and market access barriers
Market Trends and Drivers
- Growing prevalence of autoimmune diseases globally (~5% of the population)
- Increasing off-label use for rheumatoid arthritis and other conditions
- Rising demand for biologics with fewer side effects
- Patent expiry of competitors may create opportunities for biosimilars
Pricing and Cost Dynamics
Current Pricing (India and Emerging Markets)
- Per vial: approximately $150 to $250
- Treatment course (based on dose regimens): $6,000 to $12,000 annually
Price Factors
- Manufacturing costs: biologics have high R&D and production expenses
- Regulatory environment: pricing controls in countries like India
- Market competition: biosimilar proliferation may reduce prices
Biosimilar Prospects
- Biosimilars could introduce price competition
- Expected to reduce prices by around 20-40% upon entry
- Launch timelines projected for 2025-2027 in key markets (India, Europe)
Revenue and Sales Projections
| Year |
Estimated Global Revenue |
Assumptions |
| 2023 |
$50 million |
Limited penetration outside India, early adoption |
| 2024 |
$150 million |
Increased clinical use, expanding regulatory approvals |
| 2025 |
$300 million |
Biosimilar competition begins, regional expansion |
| 2026 |
$400 million |
Broader acceptance, off-label use increases |
Note: These projections assume moderate adoption rates, biosimilar entry in key markets, and price reductions consistent with industry trends.
Risks and Opportunities
Risks
- Patent challenges or biosimilar entry reducing prices
- Regulatory delays limiting market access
- Competition from established biologics
Opportunities
- Expansion into new indications
- Partnership or licensing deals to accelerate market penetration
- Price reductions boosting affordability and access
Key Takeaways
- NDC 49348-0511 (Itolizumab) operates within the competitive biologics market, with limited current penetration outside India.
- Pricing remains influenced by manufacturing costs, market competition, and regulatory policies.
- Revenue forecasts show gradual growth, potentially accelerating with biosimilar competition and broader indications.
- The biosimilar landscape is poised to impact prices from 2025 onward, with potential reductions of 20-40%.
FAQs
What are the main markets for Itolizumab?
Primarily India, with regulatory approvals in Mexico and Europe. U.S. trials are ongoing.
How does the price of Itolizumab compare with competitors?
It is generally less expensive than Western biologics, priced around $150-$250 per vial, but prices vary by country.
When are biosimilars expected in this space?
Entry is projected between 2025 and 2027, potentially reducing prices significantly.
What factors could hinder market growth?
Patent challenges, slow regulatory approvals outside India, and competition from established biologics.
What are the growth prospects in the autoimmune segment?
Moderate to high, driven by increasing disease prevalence, off-label use, and unmet needs for targeted therapies.
References
[1] IQVIA. (2022). Global Biologic Market Reports.
[2] Biocon Ltd. Annual Reports. (2021-2022).
[3] European Medicines Agency. (2022). Product approval summaries.
[4] Indian Drug Regulatory Authority. (2022). Approved biologics.
